Drugs Containing Excipient (Inactive Ingredient) POLYLACTIDE

Branded drugs containing POLYLACTIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	DURYSTA	bimatoprost	0023-9652	POLYLACTIDE
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-014	POLYLACTIDE	2039-01-01
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-023	POLYLACTIDE	2039-01-01
Foresee Pharmaceuticals Co Ltd	CAMCEVI	leuprolide	72851-042	POLYLACTIDE	2039-01-01

Generic drugs containing POLYLACTIDE excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	bimatoprost	0023-9652	POLYLACTIDE
Accord BioPharma Inc	leuprolide	69448-014	POLYLACTIDE
Accord BioPharma Inc	leuprolide	69448-023	POLYLACTIDE
Foresee Pharmaceuticals Co Ltd	leuprolide	72851-042	POLYLACTIDE

Polylactide Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Regulation and Patent Risk

Last updated: August 29, 2026

Polylactide, also called PLA or polylactic acid, is a biodegradable polyester used in drug-delivery systems, implants, microparticles, nanoparticles, and controlled-release formulations. Its pharmaceutical market is smaller than the broader PLA plastics market and is often reported together with PLGA, a related copolymer. The strongest commercial opportunity is in long-acting injectable products and resorbable medical devices, while regulatory qualification, batch consistency, hydrolysis control, and formulation patents limit rapid substitution.

Public market data does not isolate pharmaceutical-grade PLA reliably. The broader global PLA market is generally estimated in the low-single-digit billions of dollars, with high-single-digit to mid-teens annual growth depending on the source and market definition. Pharmaceutical and medical applications represent a minority of total PLA demand but have higher average selling prices and stronger technical barriers than packaging-grade PLA.

What is polylactide and how is it used as a pharmaceutical excipient?

Polylactide is a biodegradable aliphatic polyester made from lactic acid or lactide. It hydrolyzes into lactic acid, which is metabolized through normal physiological pathways. The polymer can be engineered through molecular weight, crystallinity, stereochemistry, particle size, and copolymer composition.

Pharmaceutical uses include:

Application	Role of PLA	Commercial relevance
Microspheres	Controls drug release over weeks or months	High for long-acting injectables
Nanoparticles	Encapsulates small molecules, peptides, and nucleic acids	Emerging
Implants	Provides a biodegradable drug reservoir	Established in selected products
Injectable depots	Forms an in situ or preformed release matrix	High development activity
Surgical devices	Resorbable sutures, anchors, and fixation systems	Medical-device market rather than pure excipient market
Oral delivery	Protects or delays release of active ingredients	Limited compared with parenteral applications

PLA is less hydrolytically labile than PLGA. That can support longer release periods, but it can also slow drug liberation and complicate complete product development. PLA is more crystalline in some stereochemical forms, which affects degradation, mechanical behavior, and drug diffusion.

How large is the pharmaceutical-grade polylactide market?

There is no consistently reported global market category for pharmaceutical-grade PLA alone. Commercial estimates frequently combine PLA with PLGA, medical-grade biodegradable polymers, or drug-delivery polymers. That creates a wide range of market values and prevents direct comparison between published forecasts.

The broader PLA market is driven mainly by packaging, fibers, films, and 3D-printing materials. Pharmaceutical applications account for a much smaller volume share but generate higher prices because manufacturers must control:

• Residual monomers and solvents
• Molecular-weight distribution
• End-group chemistry
• Sterility and bioburden
• Particle-size distribution
• Lactide stereochemistry
• Hydrolysis profile
• Extractables and leachables
• Compatibility with the active pharmaceutical ingredient

The financial profile therefore differs from commodity PLA. Pharmaceutical-grade material is sold on qualification, technical support, documentation, and supply continuity rather than price per kilogram alone.

Indicative market trajectory

Segment	Near-term direction	Principal demand driver
Commodity PLA	Growth with packaging and sustainability adoption	Plastic substitution
Medical-grade PLA	Moderate to strong growth	Resorbable devices and sutures
Pharmaceutical PLA	Strong but narrow growth	Long-acting injectables and implants
PLA/PLGA drug-delivery polymers	Strongest commercial opportunity	Depot formulations and complex generics
Research-grade PLA	Stable to moderate growth	Academic and early-stage development

A realistic base-case view is that pharmaceutical and medical PLA will grow faster than commodity PLA in percentage terms, but from a much smaller base. Revenue growth will depend more on product approvals than on polymer tonnage. A single approved depot product can create materially higher recurring demand than many early-stage formulation programs.

What drives demand for polylactide in pharmaceuticals?

The main demand driver is the expansion of long-acting and extended-release drug products. These products can reduce dosing frequency and support adherence, particularly in central nervous system, endocrine, infectious disease, and reproductive-health indications.

Key commercial drivers include:

1. Long-acting injectable products for chronic diseases.
2. Complex generic products requiring differentiated release mechanisms.
3. Biodegradable implants that avoid removal procedures.
4. Injectable formulations for peptides and other short-half-life drugs.
5. Drug-device combinations requiring controlled degradation.
6. Growth in specialty pharmaceuticals where formulation barriers support pricing.

PLA demand is also linked to development of resorbable medical devices. In that market, polymer qualification may occur under medical-device rules rather than through an excipient approval pathway.

The principal technical constraint is release control. Drug loading, polymer molecular weight, particle morphology, porosity, crystallinity, and sterilization can materially change the release curve. A formulation that works in one product cannot be transferred automatically to another active ingredient.

How does PLA compare with PLGA, PCL, and lipid-based delivery systems?

PLGA is the closest competing polymer. It generally degrades faster than PLA because glycolic acid units increase hydrolysis. PLA is more suitable when a longer release interval or greater structural stability is required.

Polymer or system	Relative degradation	Typical strength	Main limitation
PLA	Slow to moderate	Longer release and structural stability	Slower drug liberation and possible crystallinity effects
PLGA	Moderate to fast	Tunable release and extensive regulatory history	Acidic degradation products and burst release
PCL	Slow	Long-duration delivery and flexibility	Very slow degradation can delay drug release
Lipid nanoparticles	Not polymer-degradation dependent	Strong for nucleic acids and some biologics	Stability, cold chain, and manufacturing complexity
Hyaluronic acid	Biocompatibility and injectability	Hydrogels and localized delivery	Faster degradation unless chemically modified
Cellulose derivatives	Established oral excipient use	Tablets and modified-release dosage forms	Limited suitability for depot injectables

PLGA has a broader pharmaceutical track record, particularly in microspheres and injectable depots. PLA’s competitive position improves when the product requires long release, higher mechanical strength, or a lower hydrolysis rate.

What is the FDA regulatory status of polylactide as an excipient?

FDA status is application-specific. PLA does not have a universal approval that permits use in every dosage form, route, molecular-weight range, or drug product.

Developers must establish suitability through the applicable drug or device pathway. Relevant issues include:

• Identity and composition of the polymer
• Molecular weight and polydispersity
• Residual lactide and process impurities
• Degradation products
• Sterilization compatibility
• Local and systemic tolerability
• Drug-polymer interaction
• Release specifications
• Manufacturing controls

FDA’s Inactive Ingredient Database can provide precedent for specific inactive ingredients, routes, and dosage forms, but an entry does not automatically establish approval for every new use. Developers also rely on prior approved products, Drug Master Files, supplier documentation, and product-specific nonclinical and clinical data.[1]

For injectable products, the regulatory burden is materially higher than for oral formulations. The polymer’s physical properties can affect bioavailability, local inflammation, dose dumping, and product shelf life.

Does polylactide have GRAS status for pharmaceutical use?

Food-contact or food-use status does not establish pharmaceutical acceptability. PLA may have food, packaging, or medical-device uses under separate regulatory frameworks, but pharmaceutical use requires product-specific qualification. FDA’s excipient review principles distinguish safety and suitability in the intended route and dosage form.[2]

What patents protect pharmaceutical polylactide formulations?

The base PLA polymer is mature technology, and foundational composition and generic biodegradable-polymer patents are generally expired or near expiration. Commercial protection now concentrates on specific applications.

The most relevant patent categories are:

Patent category	Typical protected subject matter	Risk level
Polymer composition	Stereochemistry, molecular-weight range, end groups	Moderate
Microsphere formulation	Particle size, drug loading, porosity, release profile	High
Depot injection	Solvent systems, injectability, residence time	High
Implant design	Geometry, drug distribution, degradation profile	Moderate to high
Manufacturing process	Emulsion, solvent removal, crystallization, sterilization	Moderate
Combination therapy	Specific active ingredient plus PLA system	High
Method of treatment	Dosing interval and therapeutic use	High where enforceable
Drug-device combination	Polymer reservoir and delivery apparatus	Moderate to high

Patent strength depends on whether claims cover the polymer itself or the complete drug product. A broad PLA composition claim is more vulnerable to prior art and design-around strategies. A claim tied to a specific active ingredient, release profile, particle distribution, and clinical dosing regimen can be more commercially significant.

Patent expiration dates must be assessed patent by patent, including terminal disclaimers, patent-term adjustment, pediatric extensions, and jurisdiction-specific rules. A generic manufacturer may still face formulation or method-of-use patents after an earlier polymer patent has expired.

What is the Orange Book status of polylactide products?

PLA itself is not generally listed in the Orange Book as a standalone pharmaceutical product. Orange Book listings attach to approved drug products and identify patents submitted by the applicant for those products.[3]

The relevant patent risks arise when PLA is incorporated into an approved injectable, implant, or extended-release product. Listed patents may cover:

• The drug formulation
• The polymer-drug matrix
• The delivery system
• The method of treatment
• The dosing regimen

A generic applicant may submit a Paragraph IV certification against listed patents. A Paragraph IV notice can trigger patent litigation and a 30-month stay of approval under applicable conditions.[4] The absence of an Orange Book listing for PLA as a material does not eliminate product-level patent risk.

Which companies supply pharmaceutical-grade PLA?

The competitive supplier landscape includes specialist polymer manufacturers, medical-device material suppliers, and drug-delivery companies with proprietary grades.

Representative suppliers and platforms include:

• Evonik, through RESOMER biodegradable polymers
• Corbion, through PURASORB medical-grade polymers
• Poly-Med
• Durect and related drug-delivery technology platforms
• Mitsui Chemicals and other industrial producers with medical-grade PLA capability
• Specialized contract manufacturers producing polymeric microspheres or implants

Supplier competition is constrained by customer qualification. Changing polymer suppliers can require comparability work, process revalidation, stability studies, and potentially regulatory filings. This creates switching costs and supports multi-year supply agreements.

The most defensible supplier position belongs to companies that provide polymer grades plus formulation support, analytical methods, regulatory files, and manufacturing know-how. Commodity resin capacity alone has limited value in pharmaceutical applications.

What licensing deals and partnerships affect the PLA market?

Commercial activity is usually structured around drug-delivery technology licenses, contract development agreements, and supply arrangements rather than licenses for PLA chemistry alone.

Typical transaction structures include:

• Exclusive rights to a depot formulation
• Regional rights for an injectable product
• Polymer supply linked to a development program
• Joint development of microspheres or implants
• Contract manufacturing of clinical or commercial batches
• Technology transfer with milestone and royalty payments

The value of these deals depends on the active ingredient and clinical program. PLA is usually an enabling component, not the primary economic asset. Revenue exposure therefore concentrates in the approved drug product, not in polymer sales alone.

What litigation and generic entry risks exist for PLA products?

PLA-related litigation is more likely to involve a finished drug, medical device, or formulation process than the polymer as an isolated raw material.

Generic entry risks include:

1. A Paragraph IV challenge to formulation or method-of-use patents.
2. A design-around using PLGA, PCL, or a different molecular-weight grade.
3. An abbreviated pathway challenge to an injectable depot.
4. Clinical or bioequivalence requirements that delay approval.
5. Supplier changes that trigger comparability concerns.
6. Manufacturing patents covering microsphere formation or sterilization.
7. Device patents covering the implant or delivery mechanism.

Long-acting injectable generics face higher development costs than conventional oral generics. Bioequivalence may require pharmacokinetic, pharmacodynamic, in vitro release, immunogenicity, or clinical evidence depending on the product. The technical burden can delay entry even when core polymer patents have expired.

How strong is the pharmaceutical polylactide patent estate?

The PLA patent estate is moderate at the base-material level and stronger at the product level.

Base polymer

Foundational PLA synthesis and biodegradable-polymer patents provide limited exclusionary power where they have expired or where alternative production routes are available. Suppliers can differentiate through purity, stereochemistry, molecular-weight control, and documentation rather than through broad composition claims alone.

Formulation and delivery

Formulation patents are more commercially important. Claims can cover a specific drug-polymer ratio, particle-size distribution, release period, solvent system, or injection process. These claims may be difficult to invalidate if supported by strong analytical and clinical data, but they can often be designed around with a different polymer ratio, particle morphology, or manufacturing process.

Manufacturing know-how

Trade secrets can be as important as patents. Emulsion conditions, solvent-removal rates, drying parameters, sterilization cycles, and scale-up controls may determine whether a competitor can reproduce the commercial product. Manufacturing know-how is particularly relevant where patent claims are narrow.

What is the financial trajectory for pharmaceutical polylactide?

The sector has a positive long-term trajectory but uneven near-term revenue realization.

Base case

Revenue grows through expanded use in long-acting injectables, resorbable implants, and complex generic development. Growth remains faster than conventional excipient demand, but the market stays niche relative to oral excipients and commodity PLA.

Upside case

Several high-value depot or implant products reach approval, creating recurring demand for validated polymer grades. Supplier margins improve through technical services, regulatory support, and proprietary grades.

Downside case

PLGA, lipid nanoparticles, PCL, and non-polymeric delivery systems capture new programs. Clinical failures, injectable manufacturing constraints, or unfavorable release profiles reduce conversion from research demand to commercial volume.

Financial performance is likely to remain lumpy. Polymer suppliers may record limited revenue during early development, followed by a sharp increase after product approval. A single customer program can materially affect utilization at a specialist manufacturing site.

What geographic markets offer the strongest growth?

North America and Europe remain important for high-value drug-delivery development and regulatory precedent. Asia-Pacific has the strongest manufacturing and volume-growth potential, supported by polymer capacity, generic-drug development, medical-device production, and expanding pharmaceutical manufacturing.

Region	Market characteristics
United States	Highest value for approved complex injectables and patent-protected products
Europe	Strong medical-device and specialty-pharmaceutical base; centralized and national regulatory considerations
China	Growing polymer manufacturing and domestic pharmaceutical development
Japan	Advanced medical-device and drug-delivery applications with demanding qualification standards
India	Strong generic-development base and increasing interest in complex injectables
South Korea	Growing biologics, injectable, and advanced-materials manufacturing

Geographic protection depends on product patents, manufacturing patents, regulatory approvals, and supplier qualification. A polymer supplier may have global manufacturing capability while holding limited product-level patent rights.

Key takeaways

• Pharmaceutical-grade PLA is a high-value niche within the larger PLA and biodegradable-polymer markets.
• Public market estimates often combine PLA with PLGA and medical-device materials, so standalone pharmaceutical revenue is difficult to isolate.
• Long-acting injectables, implants, and complex generics are the main growth engines.
• PLGA has broader pharmaceutical precedent, while PLA is competitive where slower degradation and longer release are required.
• FDA acceptability is product-specific and depends on route, polymer grade, impurities, degradation, and manufacturing controls.
• Orange Book risk attaches to approved drug products, not to PLA as a standalone material.
• Base-polymer patents offer limited protection; formulation, method-of-use, manufacturing, and drug-device patents provide the main commercial barriers.
• Supplier qualification, process know-how, and regulatory documentation can create stronger practical barriers than polymer composition patents.
• Revenue growth is likely to be approval-driven and uneven, with substantial upside from successful depot products.

FAQs about pharmaceutical polylactide

Is PLA safer than PLGA in injectable drug delivery?

Neither polymer is categorically safer. Safety depends on polymer grade, degradation rate, dose, administration route, impurities, local tissue exposure, and the active ingredient. PLA may degrade more slowly, while PLGA can generate more acidic degradation products during hydrolysis.

Can a generic drug manufacturer replace PLGA with PLA?

Not without redevelopment and regulatory support. The polymers produce different release profiles, degradation kinetics, mechanical properties, and local environments. A substitution may require new formulation, analytical, stability, bioequivalence, and clinical work.

Does pharmaceutical PLA require a Drug Master File?

A Drug Master File may support FDA review, but it does not replace the applicant’s responsibility to demonstrate suitability in the finished drug product. The need depends on the supplier’s regulatory strategy and the sponsor’s filing.

Is polylactide used in biologic drug delivery?

Yes. PLA and PLA-based systems have been investigated for peptides, proteins, vaccines, and nucleic acids. Commercial adoption is constrained by protein stability, encapsulation stress, burst release, and sterilization requirements.

What is the largest commercial risk for PLA excipient suppliers?

The largest risk is failure to convert development programs into approved products. Early-stage demand can be substantial in technical terms but generate limited recurring revenue until a drug or device receives approval and reaches commercial scale.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. U.S. Food and Drug Administration. (2009). Guidance for industry: Nonclinical studies for the safety evaluation of pharmaceutical excipients. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-studies-safety-evaluation-pharmaceutical-excipients
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (2017). MPEP section 2810: Notice of paragraph IV certification. U.S. Patent and Trademark Office. https://www.uspto.gov/web/offices/pac/mpep/s2810.html
5. U.S. Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. https://www.usp.org
6. International Organization for Standardization. (2018). ISO 10993-1: Biological evaluation of medical devices: Part 1. ISO.